Tuesday, March 28, 2023
This article is intended for primary care clinicians, endocrinologists, diabetologists, and other specialists who care for patients at risk for type 2 diabetes.
The goal of this activity is to provide medical news to primary care clinicians and other healthcare professionals in order to enhance patient care.
Upon completion of this activity, participants will be able to:
As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 0.25
AMA PRA Category 1 Credit(s)™
. Physicians should only claim credit commensurate with the extent of their participation in the activity. Medscape Medical News has been reviewed and is acceptable for up to 350 Prescribed credits by the American Academy of Family Physicians. AAFP accreditation begins 09/01/08. Term of approval is for 1 year from this date. This activity is approved for 0.25 Prescribed credits. Credit may be claimed for 1 year from the date of this activity.
Note: Total credit is subject to change based on topic selection and article length.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 5 years; at any point within this time period you can print
out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.
*The credit that you receive is based on your user profile.
CME Released: 9/3/2008
Valid for credit through: 9/3/2009
processing....
September 3, 2008 — Adiponectin is inversely linked with the risk for type 2 diabetes in women, but resistin is not, according to the results of a prospective, nested case-control study reported in the September 2 issue of the Annals of Internal Medicine. The study authors suggest that adiponectin may be a marker for type 2 diabetes.
"Adiponectin and resistin are recently discovered adipokines that may provide a molecular link between adiposity and type 2 diabetes," write Christin Heidemann, DrPH, MSc, from Harvard School of Public Health, Massachusetts General Hospital in Boston, and colleagues.
The goal of this study was to determine whether total adiponectin and resistin and high-molecular-weight adiponectin and resistin are linked to a subsequent risk for type 2 diabetes, independent of obesity and other known risk factors for diabetes.
The study cohort consisted of 1038 women enrolled in the Nurses' Health Study who were initially healthy at baseline but who went on to have type 2 diabetes after blood sampling (1989-1990) through 2002. Plasma concentrations of total adiponectin and resistin and high-molecular weight adiponectin and resistin in these case participants were compared with those in 1136 matched-control participants.
Adiponectin levels were associated with a significantly lower risk for type 2 diabetes in multivariate models that adjusted for body mass index (BMI). For the highest quintiles vs the lowest quintiles, odds ratio (OR) was 0.17 (95% confidence interval [CI], 0.12 - 0.25) for total adiponectin and 0.10 (95% CI, 0.06 - 0.15) for high-molecular-weight adiponectin. Even after adjustment for total adiponectin, a higher ratio of high-molecular-weight adiponectin to total adiponectin was associated with a statistically significantly lower risk for type 2 diabetes (OR, 0.45; 95% CI, 0.31 - 0.65).
Higher resistin levels were associated with a higher risk for diabetes in the multivariate model without BMI (OR, 1.68; 95% CI, 1.25 - 2.25). However, this association was no longer statistically significant after adjustment for BMI (OR, 1.28; 95% CI, 0.93 - 1.76).
Limitations of this study include study sample composed mainly of white women; possible residual confounding from imperfectly measured or unmeasured variables; and results based on single measurements of the adipokines, which therefore may not reflect long-term exposure to these hormones.
"Adiponectin is strongly and inversely associated with risk for diabetes, independent of body mass index, whereas resistin is not," the study authors write. "The ratio of high-molecular-weight to total adiponectin is related to risk for diabetes independent of total adiponectin, suggesting an important role of the relative proportion of high-molecular-weight adiponectin in diabetes pathogenesis....In contrast, the positive association between resistin and type 2 diabetes was largely explained by BMI."
The National Institutes of Health and the Intramural Research Program of the National Institute of Child Health & Human Development supported this study. Dr. Heidemann was supported by fellowships of the German Academic Exchange Service and the Hans & Eugenia Juetting Foundation. One study author received a Career Development Award from the American Diabetes Association. Another study author was supported by discretionary grants from the Tanita Corp and Beth Israel Deaconess Medical Center. The remaining study authors have disclosed no relevant financial relationships.
Ann Intern Med. 2008;149:307-316.
Adipose tissue secretes various hormones and cytokines, known as adipokines, which may be a connecting molecular link between adiposity and type 2 diabetes. Adiponectin and resistin are adipokines that may be especially important in the relationship of excess adiposity to type 2 diabetes.
In contrast to other adipokines, adiponectin concentrations are paradoxically decreased in obese persons vs lean persons. Prospective studies have shown a decreased risk for type 2 diabetes with increasing concentrations of total adiponectin. Although high-molecular-weight adiponectin is the most biologically active form, few epidemiologic studies have evaluated high-molecular-weight adiponectin separately from total adiponectin.
